Goldman Sachs Group Inc. set a GBX 4,000 ($52.21) target price on AstraZeneca plc (LON:AZN) in a research report sent to investors on Tuesday morning. The firm currently has a a sell rating on the biopharmaceutical company’s stock.
Several other brokerages have also issued reports on AZN. JPMorgan Chase & Co. reissued a neutral rating and issued a GBX 4,900 ($63.96) target price (up previously from GBX 4,800 ($62.66)) on shares of AstraZeneca plc in a research report on Monday, August 8th. Deutsche Bank AG reissued a buy rating and issued a GBX 5,800 ($75.71) target price on shares of AstraZeneca plc in a research report on Monday, August 8th. Jefferies Group set a GBX 5,400 ($70.49) price objective on AstraZeneca plc and gave the company a neutral rating in a research report on Monday, August 8th. Shore Capital reaffirmed a hold rating on shares of AstraZeneca plc in a research report on Tuesday, August 9th. Finally, Beaufort Securities reaffirmed a hold rating on shares of AstraZeneca plc in a research report on Wednesday, August 10th. Five equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. AstraZeneca plc has a consensus rating of Hold and an average price target of GBX 4,937.91 ($64.46).
Shares of AstraZeneca plc (LON:AZN) traded down 0.04% during mid-day trading on Tuesday, hitting GBX 5023.00. The company’s stock had a trading volume of 1,040,959 shares. The stock’s 50 day moving average price is GBX 5,009.44 and its 200 day moving average price is GBX 4,418.92. The company’s market cap is GBX 63.54 billion. AstraZeneca plc has a 52-week low of GBX 3,680.00 and a 52-week high of GBX 5,505.00.
The company also recently disclosed a dividend, which was paid on Monday, September 12th. Stockholders of record on Thursday, August 11th were given a dividend of GBX 68.70 ($0.90) per share. The ex-dividend date of this dividend was Thursday, August 11th. This represents a dividend yield of 1.37%.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.